These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration. Yeboah F; Kim TE; Bill A; Dettmer U Neurobiol Dis; 2019 Dec; 132():104543. PubMed ID: 31351173 [TBL] [Abstract][Full Text] [Related]
4. Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases. Nonaka T; Watanabe ST; Iwatsubo T; Hasegawa M J Biol Chem; 2010 Nov; 285(45):34885-98. PubMed ID: 20805224 [TBL] [Abstract][Full Text] [Related]
5. Human neurodegenerative disease modeling using Drosophila. Bonini NM; Fortini ME Annu Rev Neurosci; 2003; 26():627-56. PubMed ID: 12704223 [TBL] [Abstract][Full Text] [Related]
6. From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Goedert M; Spillantini MG; Serpell LC; Berriman J; Smith MJ; Jakes R; Crowther RA Philos Trans R Soc Lond B Biol Sci; 2001 Feb; 356(1406):213-27. PubMed ID: 11260802 [TBL] [Abstract][Full Text] [Related]
7. Interaction between pathogenic proteins in neurodegenerative disorders. Jellinger KA J Cell Mol Med; 2012 Jun; 16(6):1166-83. PubMed ID: 22176890 [TBL] [Abstract][Full Text] [Related]
8. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955 [TBL] [Abstract][Full Text] [Related]
11. [Conformationally altered proteins cause neurodegenerative diseases]. Ingelsson M; Nilsson L; Basun H; Aquilonius SM; Lannfelt L Lakartidningen; 2005 Nov 21-27; 102(47):3542-3, 3545-6, 3549 passim. PubMed ID: 16408392 [TBL] [Abstract][Full Text] [Related]
12. Tau pathology: a marker of neurodegenerative disorders. Delacourte A; Buée L Curr Opin Neurol; 2000 Aug; 13(4):371-6. PubMed ID: 10970052 [TBL] [Abstract][Full Text] [Related]
13. Cellular Models for the Study of Prions. Holmes BB; Diamond MI Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27815306 [TBL] [Abstract][Full Text] [Related]
14. Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders. Li X; James S; Lei P J Mol Neurosci; 2016 Nov; 60(3):298-304. PubMed ID: 27629562 [TBL] [Abstract][Full Text] [Related]
15. The expanding realm of prion phenomena in neurodegenerative disease. Frost B; Diamond MI Prion; 2009; 3(2):74-7. PubMed ID: 19448400 [TBL] [Abstract][Full Text] [Related]
16. Interaction between α-synuclein and other proteins in neurodegenerative disorders. Jellinger KA ScientificWorldJournal; 2011; 11():1893-907. PubMed ID: 22125446 [TBL] [Abstract][Full Text] [Related]
17. Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein. Martinez-Valbuena I; Valenti-Azcarate R; Amat-Villegas I; Marcilla I; Marti-Andres G; Caballero MC; Riverol M; Tuñon MT; Fraser PE; Luquin MR Acta Neuropathol Commun; 2021 Apr; 9(1):64. PubMed ID: 33832546 [TBL] [Abstract][Full Text] [Related]
18. [Animal models of neurodegenerative diseases]. Langui D; Lachapelle F; Duyckaerts C Med Sci (Paris); 2007 Feb; 23(2):180-6. PubMed ID: 17291428 [TBL] [Abstract][Full Text] [Related]
19. The significance of tau and alpha-synuclein inclusions in neurodegenerative diseases. Goedert M Curr Opin Genet Dev; 2001 Jun; 11(3):343-51. PubMed ID: 11377973 [TBL] [Abstract][Full Text] [Related]
20. Following the leader: fibrillization of alpha-synuclein and tau. Frasier M; Wolozin B Exp Neurol; 2004 Jun; 187(2):235-9. PubMed ID: 15144849 [No Abstract] [Full Text] [Related] [Next] [New Search]